Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group

Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group

Patients with advanced triple-negative breast cancer (TNBC) benefit from treatment with atezolizumab, provided that the tumor contains ≥1% of PD-L1/SP142-positive immune cells. Numbers of tumor-infiltrating lymphocytes (TILs) vary strongly according to the anatomic localization of TNBC metastases. W...

Full description

Bibliographic Details
Main Authors: Mieke R. Van Bockstal, Maxine Cooks, Iris Nederlof, Mariël Brinkhuis, Annemiek Dutman, Monique Koopmans, Loes Kooreman, Bert van der Vegt, Leon Verhoog, Celine Vreuls, Pieter Westenend, Marleen Kok, Paul J. van Diest, Inne Nauwelaers, Nele Laudus, Carsten Denkert, David Rimm, Kalliopi P. Siziopikou, Scott Ely, Dimitrios Zardavas, Mustimbo Roberts, Giuseppe Floris, Johan Hartman, Balazs Acs, Dieter Peeters, John M.S. Bartlett, Els Dequeker, Roberto Salgado, Fabiola Giudici, Stefan Michiels, Hugo Horlings, Carolien H. M. van Deurzen
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Cancers
Subjects:
PD-L1
SP142
triple-negative breast cancer
TNBC
tumor-infiltrating lymphocytes
TILs
Online Access:https://www.mdpi.com/2072-6694/13/19/4910

Internet

https://www.mdpi.com/2072-6694/13/19/4910

Similar Items